Related Experiment Video
Updated: Aug 2, 2025
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
Mouse models for immuno-oncology
Marcus Bosenberg1, Edison T Liu2, Chun I Yu2
1Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.
Abstract:
Realizing the clinical promise of cancer immunotherapy is hindered by gaps in our knowledge of in vivo mechanisms underlying treatment response as well as treatment limiting toxicity. Preclinical in vivo model systems and technologies are required to address these knowledge gaps and to surmount the challenges faced in the clinical application of immunotherapy. Mice are commonly used for basic and translational research to support development and testing of immune interventions, including for cancer. Here, we discuss the advantages and the limitations of current models as well as future developments.
Insights
Understanding in vivo mechanisms is crucial for advancing cancer immunotherapy. Preclinical mouse models are vital for studying treatment responses and toxicities, but require further development.
Area of Science:
- Immunology
- Oncology
- Preclinical Research
Background:
- Clinical success of cancer immunotherapy is limited by incomplete understanding of in vivo treatment response and toxicity mechanisms.
- Effective preclinical models are essential to bridge this knowledge gap for advancing cancer immunotherapy.
Purpose of the Study:
- To review the advantages and limitations of current in vivo preclinical models for cancer immunotherapy research.
- To discuss future developments in preclinical model systems for immunotherapy.
Main Methods:
- Literature review and discussion of existing preclinical in vivo model systems.
- Analysis of mouse models commonly used in cancer immunotherapy research.
Main Results:
- Mice are frequently utilized in basic and translational research for immune interventions in cancer.
- Current models offer benefits but also possess limitations that need addressing for improved immunotherapy development.
Conclusions:
- Further development of preclinical in vivo models is necessary to overcome challenges in clinical cancer immunotherapy.
- Advanced model systems are key to realizing the full clinical potential of cancer treatments targeting the immune system.
